SECOND REGULAR SESSION
HOUSE BILL NO. 2213
102ND GENERAL ASSEMBLY
INTRODUCED BY REPRESENTATIVE HUDSON.
4668H.01I DANARADEMANMILLER,ChiefClerk
AN ACT
To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to
controlled substances.
Be it enacted by the General Assembly of the state of Missouri, as follows:
Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu
2 thereof, to be known as section 195.017, to read as follows:
195.017. 1. The department of health and senior services shall place a substance in
2 Schedule I if it finds that the substance:
3 (1) Has high potential for abuse; and
4 (2) Has no accepted medical use in treatment in the United States or lacks accepted
5 safety for use in treatment under medical supervision.
6 2. Schedule I:
7 (1) The controlled substances listed in this subsection are included in Schedule I;
8 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and
9 salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of
10 these isomers, esters, ethers and salts is possible within the specific chemical designation:
11 (a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-
12 phenylacetamide);
13 (b) Acetylmethadol;
14 (c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
15 (d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);
16 (e) AH-7921(3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl] benzamide);
17 (f) Allylprodine;
EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.
HB 2213 2
18 (g) Alphacetylmethadol (except levoalphacetylmethadol, also known as levo-alpha-
19 acetylmethadol levothadyl acetate or LAAM);
20 (h) Alphameprodine;
21 (i) Alphamethadol;
22 (j) Alpha-methylfentanyl (N-1-(alphamethyl-beta-phenyl) ethyl-4-piperidyl)
23 propionanilide; 1-(1-methyl-2-phenylethyl)-4 ((N-propanilido) piperidine);
24 (k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-thienyl) ethyl-4-piperidinyl)-N-
25 phenylpropanamide);
26 (l) Benzethidine;
27 (m) Betacetylmethadol;
28 (n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-
29 phenylpropanamide);
30 (o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-
31 piperidinyl)-N-phenylpropanamide);
32 (p) Betameprodine;
33 (q) Betamethadol;
34 (r) Betaprodine;
35 (s) Clonitazene;
36 (t) Dextromoramide;
37 (u) Diampromide;
38 (v) Cyclopropyl fentanyl;
39 (w) Diethylthiambutene;
40 (x) Difenoxin;
41 (y) Dimenoxadol;
42 (z) Dimepheptanol;
43 (aa) Dimethylthiambutene;
44 (bb) Dioxaphetyl butyrate;
45 (cc) Dipipanone;
46 (dd) Ethylmethylthiambutene;
47 (ee) Etonitazene;
48 (ff) Etoxeridine;
49 (gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
50 isobutyramide;
51 (hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;
52 (ii) Furethidine;
53 (jj) Hydroxypethidine;
54 (kk) Ketobemidone;
HB 2213 3
55 (ll) Levomoramide;
56 (mm) Levophenacylmorphan;
57 (nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
58 phenylproanamide), its optical and geometric isomers, salts, and salts of isomers;
59 (oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-
60 phenylpropanamide);
61 (pp) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-
62 phenylacetamide);
63 (qq) Morpheridine;
64 (rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
65 (ss) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) piperazine);
66 (tt) Noracymethadol;
67 (uu) Norlevorphanol;
68 (vv) Normethadone;
69 (ww) Norpipanone;
70 (xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)
71 acetamide;
72 (yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin-yl)propionamide); other name
73 2-fluorofentanyl;
74 (zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
75 butyramide;
76 (aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)
77 propanamide);
78 (bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
79 (ccc) Phenadoxone;
80 (ddd) Phenampromide;
81 (eee) Phenomorphan;
82 (fff) Phenoperidine;
83 (ggg) Piritramide;
84 (hhh) Proheptazine;
85 (iii) Properidine;
86 (jjj) Propiram;
87 (kkk) Racemoramide;
88 (lll) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
89 phenyltetrahydrofuran-2-carboxamide);
90 (mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide);
91 (nnn) Tianeptine;
HB 2213 4
92 [(nnn)] (ooo) Tilidine;
93 [(ooo)] (ppp) Trimeperidine;
94 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
95 unless specifically excepted, whenever the existence of these salts, isomers and salts of
96 isomers is possible within the specific chemical designation:
97 (a) Acetorphine;
98 (b) Acetyldihydrocodeine;
99 (c) Benzylmorphine;
100 (d) Codeine methylbromide;
101 (e) Codeine-N-Oxide;
102 (f) Cyprenorphine;
103 (g) Desomorphine;
104 (h) Dihydromorphine;
105 (i) Drotebanol;
106 (j) Etorphine (except hydrochloride salt);
107 (k) Heroin;
108 (l) Hydromorphinol;
109 (m) Methyldesorphine;
110 (n) Methyldihydromorphine;
111 (o) Morphine methylbromide;
112 (p) Morphine methylsulfonate;
113 (q) Morphine-N-Oxide;
114 (r) Myrophine;
115 (s) Nicocodeine;
116 (t) Nicomorphine;
117 (u) Normorphine;
118 (v) Pholcodine;
119 (w) Thebacon;
120 (4) Any of the following opiate similar synthetic substances scheduled by the U.S.
121 Drug Enforcement Administration as substances that share a pharmacological profile similar
122 to fentanyl, morphine, and other synthetic opioids, unless specifically excepted or unless
123 listed in another schedule:
124 (a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
125 (b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino) cyclohexyl]–methyl benzamide).
126 (5) Any material, compound, mixture or preparation which contains any quantity of
127 the following hallucinogenic substances, their salts, isomers and salts of isomers, unless
HB 2213 5
128 specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is
129 possible within the specific chemical designation:
130 (a) Alpha-ethyltryptamine;
131 (b) 4-bromo-2,5-dimethoxyamphetamine;
132 (c) 4-bromo-2,5-dimethoxyphenethylamine;
133 (d) 2,5-dimethoxyamphetamine;
134 (e) 2,5-dimethoxy-4-ethylamphetamine;
135 (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
136 (g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;
137 (h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;
138 (i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;
139 (j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;
140 (k) 2-(2,5-Dimethoxyphenyl) ethanamine;
141 (l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;
142 (m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;
143 (n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;
144 (o) 2-(4-(Isopropylthio)-2,5-dimethoxyphenyl) ethanamine;
145 (p) 4-methoxyamphetamine;
146 (q) 5-methoxy-3,4-methylenedioxyamphetamine;
147 (r) 4-methyl-2, 5-dimethoxyamphetamine;
148 (s) 3,4-methylenedioxyamphetamine;
149 (t) 3,4-methylenedioxymethamphetamine;
150 (u) 3,4-methylenedioxy-N-ethylamphetamine;
151 (v) N-hydroxy-3, 4-methylenedioxyamphetamine;
152 (w) 3,4,5-trimethoxyamphetamine;
153 (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine;
154 (y) Alpha-methyltryptamine;
155 (z) Bufotenine;
156 (aa) Diethyltryptamine;
157 (bb) Dimethyltryptamine;
158 (cc) 5-methoxy-N,N-diisopropyltryptamine;
159 (dd) Ibogaine;
160 (ee) Lysergic acid diethylamide;
161 (ff) Marijuana or marihuana, except industrial hemp;
162 (gg) Mescaline;
163 (hh) Parahexyl;
HB 2213 6
164 (ii) Peyote, to include all parts of the plant presently classified botanically as
165 Lophophora williamsii Lemaire, whether growing or not; the seeds thereof; any extract from
166 any part of such plant; and every compound, manufacture, salt, derivative, mixture or
167 preparation of the plant, its seed or extracts;
168 (jj) N-ethyl-3-piperidyl benzilate;
169 (kk) N-methyl-3-piperidyl benzilate;
170 (ll) Psilocybin;
171 (mm) Psilocyn;
172 (nn) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
173 (cannabis plant), except industrial hemp, as well as synthetic equivalents of the substances
174 contained in the cannabis plant, or in the resinous extractives of such plant, or synthetic
175 substances, derivatives and their isomers, or both, with similar chemical structure and
176 pharmacological activity to those substances contained in the plant, such as the following:
177 a. 1 cis or trans tetrahydrocannabinol and their optical isomers;
178 b. 6 cis or trans tetrahydrocannabinol and their optical isomers;
179 c. 3,4 cis or trans tetrahydrocannabinol and their optical isomers;
180 d. Any compounds of these structures, regardless of numerical designation of atomic
181 positions covered;
182 (oo) Ethylamine analog of phencyclidine;
183 (pp) Pyrrolidine analog of phencyclidine;
184 (qq) Thiophene analog of phencyclidine;
185 (rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
186 (ss) Salvia divinorum;
187 (tt) Salvinorin A;
188 (uu) Synthetic cannabinoids:
189 a. Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-
190 (1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl,
191 haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-
192 (4-morpholinyl)ethylgroup,whetherornotfurthersubstitutedintheindoleringtoanyextent,
193 whether or not substituted in the naphthyl ring to any extent. Including, but not limited to:
194 (i) AM2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
195 (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
196 (iii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
197 (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
198 (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
199 (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
200 (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
HB 2213 7
201 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
202 (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
203 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
204 (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
205 (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
206 (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
207 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at
208 the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
209 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
210 or not further substituted in the pyrrole ring to any extent, whether or not substituted in the
211 naphthyl ring to any extent;
212 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by
213 substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
214 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
215 ethylgroup, whetheror notfurther substitutedin the indenering to anyextent,whether or not
216 substituted in the naphthyl ring to any extent;
217 d. Any compound structurally derived from 3-phenylacetylindole by substitution at
218 the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
219 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether
220 or not further substituted in the indole ring to any extent, whether or not substituted in the
221 phenyl ring to any extent. Including, but not limited to:
222 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
223 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
224 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
225 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
226 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
227 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
228 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,
229 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
230 ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but
231 not limited to CP 47, 497 and homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
232 methyloctan-2-yl)phenol, where side chain n=5, and homologues where side chain n-4,6, or
233 7;
234 f. Any compound containing a 3-(benzoyl)indole structure with substitution at the
235 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
236 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group,
HB 2213 8
237 whether or not further substituted in the indole ring to any extent and whether or not
238 substituted in the phenyl ring to any extent. Including, but not limited to:
239 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
240 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-19 and RCS-4);
241 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-
242 2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
243 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
244 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
245 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
246 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
247 j. Dimethylheptylpyran, or DMHP;
248 (6) Any material, compound, mixture or preparation containing any quantity of the
249 followingsubstanceshavingadepressanteffectonthecentralnervoussystem,includingtheir
250 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
251 isomers is possible within the specific chemical designation:
252 (a) Gamma-hydroxybutyric acid;
253 (b) Mecloqualone;
254 (c) Methaqualone;
255 (7) Any material, compound, mixture or preparation containing any quantity of the
256 following substances having a stimulant effect on the central nervous system, including their
257 salts, isomers and salts of isomers:
258 (a) Aminorex;
259 (b) N-benzylpiperazine;
260 (c) Cathinone;
261 (d) Fenethylline;
262 (e) 3-Fluoromethcathinone;
263 (f) 4-Fluoromethcathinone;
264 (g) Mephedrone, or 4-methylmethcathinone;
265 (h) Methcathinone;
266 (i) 4-methoxymethcathinone;
267 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
268 oxazolamine);
269 (k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3-Benzodioxol-5-yl)-2-(1-
270 pyrrolidinyl)-1-pentanone;
271 (l) Methylone, or 3,4-Methylenedioxymethcathinone;
272 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
273 (n) N-ethylamphetamine;
HB 2213 9
274 (o) N,N-dimethylamphetamine;
275 (p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC);
276 (q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-
277 PB-22);
278 (r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
279 carboxamide (AB-FUBINACA);
280 (s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
281 (ADB-PINACA);
282 (8) A temporary listing of substances subject to emergency scheduling under federal
283 law shall include any material, compound, mixture or preparation which contains any
284 quantity of the following substances:
285 (a) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical,
286 positional, and geometric isomers, salts, and salts of isomers;
287 (b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone,
288 its optical, positional, and geometric isomers, salts, and salts of isomers;
289 (c) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and
290 geometric isomers, salts, and salts of isomers;
291 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical,
292 positional, and geometric isomers, salts, and salts of isomers;
293 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical,
294 positional, and geometric isomers, salts, and salts of isomers;
295 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical,
296 positional, and geometric isomers, salts, and salts of isomers;
297 (g) 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts,
298 and salts of isomers;
299 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric
300 isomers, salts, and salts of isomers;
301 (i) Alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers,
302 salts, and salts of isomers;
303 (j) Butylone,its optical, positional, and geometricisomers,salts, andsaltsof isomers;
304 (k) Pentedrone, its optical, positional, and geometric isomers, salts, and salts of
305 isomers;
306 (l) Pentylone, its optical, positional, and geometric isomers, salts, and salts of
307 isomers;
308 (m) Naphyrone, its optical, positional, and geometric isomers, salts, and salts of
309 isomers;
HB 2213 10
310 (n) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers,
311 salts, and salts of isomers;
312 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
313 carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers;
314 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its
315 optical, positional, and geometric isomers, salts, and salts of isomers;
316 (q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-yl)methanone, its optical,
317 positional, and geometric isomers, salts, and salts of isomers;
318 (r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-4-yl]-N-phenylpropionamide,
319 its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
320 (s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and
321 geometric isomers, salts, and salts of isomers;
322 (t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
323 carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers;
324 (u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-
325 dimethylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers;
326 (v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, its
327 optical, positional, and geometric isomers, salts, and salts of isomers;
328 (w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, its optical,
329 positional, and geometric isomers, salts, and salts of isomers;
330 (x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
331 carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers;
332 (y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
333 dimethylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers;
334 (z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-
335 dimethylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers;
336 (aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide, its isomers,
337 esters, ethers, salts, and salts of isomers, esters, and ethers;
338 (bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
339 its optical, positional, and geometric isomers, salts, and salts of isomers;
340 (cc) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide, its isomers,
341 esters, ethers, salts, and salts of isomers, esters, and ethers;
342 (dd) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its isomers, esters, ethers,
343 salts, and salts of isomers, esters, and ethers;
344 (ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,itsisomers,esters,
345 ethers, salts, and salts of isomers, esters, and ethers;
HB 2213 11
346 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers,
347 esters, ethers, salts, and salts of isomers, esters, and ethers;
348 (gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, its isomers,
349 esters, ethers, salts, and salts of isomers, esters, and ethers;
350 (hh) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide, its isomers, esters,
351 ethers, salts, and salts of isomers, esters, and ethers;
352 (ii) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide, its isomers,
353 esters, ethers, salts, and salts of isomers, esters, and ethers;
354 (jj) Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of
355 isomers, esters, and ethers. Fentanyl-related substance shall mean any substance not
356 otherwise listed under another Drug Enforcement Administration Controlled Substance Code
357 Number, and for whichno exemption orapproval is in effectunder section 505 of theFederal
358 Food, Drug, and Cosmetic Act, 21 U.S.C. Section 355, that is structurally related to fentanyl
359 by one or more of the following modifications:
360 a. Replacement of the phenyl portion of the phenethyl group by any monocycle,
361 whether or not further substituted in or on the monocycle;
362 b. Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl,
363 halo, haloalkyl, amino or nitro groups;
364 c. Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether,
365 hydroxyl, amino or nitro groups;
366 d. Replacement of the aniline ring with any aromatic monocycle, whether or not
367 further substituted in or on the aromatic monocycle; or
368 e. Replacement of the N-propionyl group by another acyl group;
369 (kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical,
370 positional, and geometric isomers, salts, and salts of isomers (NM2201; CBL2201);
371 (ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
372 carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (5F-
373 AB-PINACA);
374 (mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its
375 optical, positional, and geometric isomers, salts, and salts of isomers (4-CN-CUMYL-
376 BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-4CN-
377 BINACA; SGT-78);
378 (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate,
379 its optical, positional, and geometric isomers, salts, and salts of isomers (MMB-CHMICA,
380 AMB-CHMICA);
HB 2213 12
381 (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-
382 carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (5F-
383 CUMYL-P7AICA);
384 (pp) N-ethylpentylone, its optical, positional, and geometric isomers, salts, and salts
385 of isomers (ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one);
386 (qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate,
387 its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: 5F-
388 EDMB-PINACA);
389 (rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate,
390 its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: 5F-
391 MDMB-PICA);
392 (ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
393 positional, and geometric isomers, salts, and salts of isomers (trivial names: FUB-AKB48;
394 FUB-APINACA; AKB48 N-(4-FLUOROBENZYL));
395 (tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its
396 optical, positional, and geometric isomers, salts, and salts of isomers (trivial names: 5F-
397 CUMYL-PINACA; SGT-25);
398 (uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone,
399 its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: FUB-
400 144);
401 (vv) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts
402 of isomers (Other name: 2-(ethylamino)-1-phenylhexan-1-one);
403 (ww) alpha-pyrrolidinohexanophenone,itsoptical,positional,andgeometricisomers,
404 salts,and salts of isomers(Other names: α-PHP; alpha-pyrrolidinohexiophenone; 1-phenyl-2-
405 (pyrrolidin-1-yl)hexan-1-one);
406 (xx) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric
407 isomers, salts, and salts of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4-
408 methylphenyl)pentan-1-one);
409 (yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric
410 isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-
411 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
412 (zz) alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers,
413 salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
414 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric
415 isomers, salts, and salts of isomers (Other names: 4-chloro-α-PVP; 4'-chloro-alpha-
416 pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
HB 2213 13
417 (9) Khat, to include all parts of the plant presently classified botanically as catha
418 edulis,whethergrowingornot;theseedsthereof;anyextractfromanypartofsuchplant;and
419 everycompound,manufacture,salt,derivative,mixture,orpreparationoftheplant,itsseedor
420 extracts.
421 3. The department of health and senior services shall place a substance in Schedule II
422 if it finds that:
423 (1) The substance has high potential for abuse;
424 (2) The substance has currently accepted medical use in treatment in the United
425 States, or currently accepted medical use with severe restrictions; and
426 (3) The abuse of the substance may lead to severe psychic or physical dependence.
427 4. The controlled substances listed in this subsection are included in Schedule II:
428 (1) Any of the following substances whether produced directly or indirectly by
429 extraction from substances of vegetable origin, or independently by means of chemical
430 synthesis, or by combination of extraction and chemical synthesis:
431 (a) Opium and opiate; and any salt, compound, derivative or preparation of opium or
432 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine,
433 nalmefene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the
434 following:
435 a. Raw opium;
436 b. Opium extracts;
437 c. Opium fluid;
438 d. Powdered opium;
439 e. Granulated opium;
440 f. Tincture of opium;
441 g. Codeine;
442 h. Dihydroetorphine;
443 i. Ethylmorphine;
444 j. Etorphine hydrochloride;
445 k. Hydrocodone;
446 l. Hydromorphone;
447 m. Metopon;
448 n. Morphine;
449 o. Oripavine;
450 p. Oxycodone;
451 q. Oxymorphone;
452 r. Thebaine;
HB 2213 14
453 (b) Any salt, compound, derivative, or preparation thereof which is chemically
454 equivalent or identical with any of the substances referred to in this subdivision, but not
455 including the isoquinoline alkaloids of opium;
456 (c) Opium poppy and poppy straw;
457 (d) Cocaleavesandanysalt,compound,derivative,orpreparationofcocaleaves,and
458 any salt, compound, derivative, or preparation thereof which is chemically equivalent or
459 identical with any of these substances, but not including the following:
460 a. Decocainized coca leaves or extractions of coca leaves, which extractions do not
461 contain cocaine or ecgonine; or
462 b. Ioflupane;
463 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid,
464 solid or powder form which contains the phenanthrene alkaloids of the opium poppy);
465 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and
466 salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible
467 within the specific chemical designation, dextrorphan and levopropoxyphene excepted:
468 (a) Alfentanil;
469 (b) Alphaprodine;
470 (c) Anileridine;
471 (d) Bezitramide;
472 (e) Bulk dextropropoxyphene;
473 (f) Carfentanil;
474 (g) Dihydrocodeine;
475 (h) Diphenoxylate;
476 (i) Fentanyl;
477 (j) Isomethadone;
478 (k) Levo-alphacetylmethadol;
479 (l) Levomethorphan;
480 (m) Levorphanol;
481 (n) Metazocine;
482 (o) Methadone;
483 (p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
484 (q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-
485 carboxylic acid;
486 (r) Pethidine (meperidine);
487 (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
488 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
489 (u) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperdine-4-carboxylic acid;
HB 2213 15
490 (v) Phenazocine;
491 (w) Piminodine;
492 (x) Racemethorphan;
493 (y) Racemorphan;
494 (z) Remifentanil;
495 (aa) Sufentanil;
496 (bb) Tapentadol;
497 (cc) Thiafentanil;
498 (3) Any material, compound, mixture, or preparation which contains any quantity of
499 the following substances having a stimulant effect on the central nervous system:
500 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
501 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
502 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
503 (d) Phenmetrazine and its salts;
504 (e) Methylphenidate;
505 (4) Any material, compound, mixture, or preparation which contains any quantity of
506 the following substances having a depressant effect on the central nervous system, including
507 itssalts,isomers,andsaltsofisomerswhenevertheexistenceofthosesalts,isomers,andsalts
508 of isomers is possible within the specific chemical designation:
509 (a) Amobarbital;
510 (b) Glutethimide;
511 (c) Pentobarbital;
512 (d) Phencyclidine;
513 (e) Secobarbital;
514 (5) Hallucinogenic substances:
515 (a) Any material or compound which contains any quantity of nabilone;
516 (b) Dronabinol [(-)-Δ-9-trans tetrahydrocannabinol] in an oral solution in a drug
517 product approved for marketing by the U.S. Food and Drug Administration;
518 (6) Any material, compound, mixture, or preparation which contains any quantity of
519 the following substances:
520 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
521 (b) Immediate precursors to phencyclidine (PCP):
522 a. 1-phenylcyclohexylamine;
523 b. 1-piperidinocyclohexanecarbonitrile (PCC);
524 (c) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperidine (ANPP);
525 (7) Any material, compound, mixture, or preparation which contains any quantity of
526 the following alkyl nitrites:
HB 2213 16
527 (a) Amyl nitrite;
528 (b) Butyl nitrite.
529 5. ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleIII
530 if it finds that:
531 (1) The substance has a potential for abuse less than the substances listed in
532 Schedules I and II;
533 (2) The substance has currently accepted medical use in treatment in the United
534 States; and
535 (3) Abuse of the substance may lead to moderate or low physical dependence or high
536 psychological dependence.
537 6. The controlled substances listed in this subsection are included in Schedule III:
538 (1) Any material, compound, mixture, or preparation which contains any quantity of
539 thefollowingsubstanceshavinga potentialforabuseassociatedwithastimulant effectonthe
540 central nervous system:
541 (a) Benzphetamine;
542 (b) Chlorphentermine;
543 (c) Clortermine;
544 (d) Phendimetrazine;
545 (2) Any material, compound, mixture or preparation which contains any quantity or
546 salt of the following substances or salts having a depressant effect on the central nervous
547 system:
548 (a) Any material, compound, mixture or preparation which contains any quantity or
549 salt of the following substances combined with one or more active medicinal ingredients:
550 a. Amobarbital;
551 b. Secobarbital;
552 c. Pentobarbital;
553 (b) Any suppository dosage form containing any quantity or salt of the following:
554 a. Amobarbital;
555 b. Secobarbital;
556 c. Pentobarbital;
557 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
558 salt;
559 (d) Chlorhexadol;
560 (e) Embutramide;
561 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained
562 inadrugproductforwhichanapplicationhasbeenapprovedunderSection505ofthefederal
563 Food, Drug, and Cosmetic Act;
HB 2213 17
564 (g) Ketamine, its salts, isomers, and salts of isomers;
565 (h) Lysergic acid;
566 (i) Lysergic acid amide;
567 (j) Methyprylon;
568 (k) Perampanel, and its salts, isomers, and salts of isomers;
569 (l) Sulfondiethylmethane;
570 (m) Sulfonethylmethane;
571 (n) Sulfonmethane;
572 (o) Tiletamine and zolazepam or any salt thereof;
573 (3) Nalorphine;
574 (4) Any material, compound, mixture, or preparation containing limited quantities of
575 any of the following narcotic drugs or their salts:
576 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
577 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
578 alkaloid of opium;
579 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
580 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in
581 recognized therapeutic amounts;
582 (c) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not
583 morethanninetymilligramsperdosageunit,withoneormoreactive,nonnarcoticingredients
584 in recognized therapeutic amounts;
585 (d) Not more than three hundred milligrams of ethylmorphine per one hundred
586 milliliters or not more than fifteen milligrams per dosage unit, with one or more active,
587 nonnarcotic ingredients in recognized therapeutic amounts;
588 (e) Notmorethanfivehundredmilligramsofopiumperonehundredmillilitersorper
589 onehundredgramsornotmorethantwenty-fivemilligramsperdosageunit,withoneormore
590 active nonnarcotic ingredients in recognized therapeutic amounts;
591 (f) Not more than fifty milligrams of morphine per one hundred milliliters or per one
592 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
593 amounts;
594 (5) Any material, compound, mixture, or preparation containing any of the following
595 narcotic drugs or their salts: Buprenorphine;
596 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
597 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids,
598 and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which
599 is expressly intended for administration through implants to cattle or other nonhuman species
600 and which has been approved by the Secretary of Health and Human Services for that
HB 2213 18
601 administration. If any person prescribes, dispenses, or distributes such steroid for human use,
602 such person shall be considered to have prescribed, dispensed, or distributed an anabolic
603 steroid within the meaning of this subdivision. Unless specifically excepted or unless listed
604 in another schedule, any material, compound, mixture or preparation containing any quantity
605 of the following substances, including its salts, esters and ethers:
606 (a) 3ß,17ß-dihydroxy-5α-androstane;
607 (b) 3α,17β-dihydroxy-5α-androstane;
608 (c) 5α-androstan-3,17-dione;
609 (d) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene);
610 (e) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene);
611 (f) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);
612 (g) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);
613 (h) 1-androstenedione ([5α]-androst-1-en-3,17-dione);
614 (i) 4-androstenedione (androst-4-en-3,17-dione);
615 (j) 5-androstenedione (androst-5-en-3,17-dione);
616 (k) Bolasterone (7α, 17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
617 (l) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one);
618 (m) Boldione;
619 (n) Calusterone (7β, 17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
620 (o) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one);
621 (p) Dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-
622 1,4-dien-3-one);
623 (q) Desoxymethyltestosterone;
624 (r) 4-dihydrotestosterone (17ß-hydroxy-androstan-3-one);
625 (s) Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3-one);
626 (t) Ethylestrenol (17α-ethyl-17ß-hydroxyestr-4-ene);
627 (u) Fluoxymesterone (9-fluoro-17α-methyl-11ß,17ß-dihydroxyandrost-4-en-3-one);
628 (v) Formebolone (2-formyl-17α-methyl-11α,17ß-dihydroxyandrost-1,4-dien-3-one);
629 (w) Furazabol (17α-methyl-17ß-hydroxyandrostano[2,3-c]-furazan);
630 (x) 13ß-ethyl-17ß-hydroxygon-4-en-3-one;
631 (y) 4-hydroxytestosterone (4,17ß-dihydroxy-androst-4-en-3-one);
632 (z) 4-hydroxy-19-nortestosterone (4,17ß-dihydroxy-estr-4-en-3-one);
633 (aa) Mestanolone (17α-methyl-17ß-hydroxy-5α-androstan-3-one);
634 (bb) Mesterolone (1α- methyl-17ß-hydroxy-[5α]-androstan-3-one);
635 (cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4-dien-3-one);
636 (dd) Methandriol (17α-methyl-3ß,17ß-dihydroxyandrost-5-ene);
637 (ee) Methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one);
HB 2213 19
638 (ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en-3-one);
639 (gg) 17α-methyl-3β,17β-dihydroxy-5α-androstane;
640 (hh) 17α-methyl-3α,17β-dihydroxy-5α-androstane;
641 (ii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;
642 (jj) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-
643 3-one);
644 (kk) Methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);
645 (ll) Methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one);
646 (mm) Methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one);
647 (nn) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one);
648 (oo) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-
649 3-one) (a.k.a. '17-α-methyl-1-testosterone');
650 (pp) Nandrolone (17β-hydroxyestr-4-ene-3-one);
651 (qq) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4-ene);
652 (rr) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene);
653 (ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
654 (tt) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene);
655 (uu) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5-ene);
656 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
657 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
658 (xx) Norbolethone (13β,17α-diethyl-17β-hydroxygon-4-en-3-one);
659 (yy) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3-one);
660 (zz) Norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one);
661 (aaa) Normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one);
662 (bbb) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one);
663 (ccc) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);
664 (ddd) metholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
665 one);
666 (eee) Prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole);
667 (fff) Stanolone (Δ1-dihydrotestosterone (a.k.a. 1-testosterone)(17β-hydroxy-5α-
668 androst-1-en-3-one));
669 (ggg) Stanozolol (17α-methyl-17ß-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole);
670 (hhh) Stenbolone (17ß-hydroxy-2-methyl-[5α]-androst-1-en-3-one);
671 (iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
672 lactone);
673 (jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one);
674 (kkk) Tetrahydrogestrinone (13ß,17α-diethyl-17ß-hydroxygon-4,9,11-trien-3-one);
HB 2213 20
675 (lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one);
676 (mmm) Any salt, ester, or ether of a drug or substance described or listed in this
677 subdivision,exceptananabolicsteroidwhichisexpresslyintendedforadministrationthrough
678 implants to cattle or other nonhuman species and which has been approved by the Secretary
679 of Health and Human Services for that administration;
680 (7) Dronabinol(synthetic)insesameoilandencapsulatedinasoftgelatincapsuleina
681 United States Food and Drug Administration approved drug product;
682 (8) The department of health and senior services may except by rule any compound,
683 mixture, or preparation containing any stimulant or depressant substance listed in
684 subdivisions (1) and (2) of this subsection from the application of all or any part of
685 sections 195.010 to 195.320 if the compound, mixture, or preparation contains one or more
686 activemedicinalingredientsnothavingastimulantordepressanteffectonthecentralnervous
687 system, and if the admixtures are included therein in combinations, quantity, proportion, or
688 concentration that vitiate the potential for abuse of the substances which have a stimulant or
689 depressant effect on the central nervous system.
690 7. The department of health and senior services shall place a substance in Schedule
691 IV if it finds that:
692 (1) The substance has a low potential for abuse relative to substances in Schedule III;
693 (2) The substance has currently accepted medical use in treatment in the United
694 States; and
695 (3) Abuse of the substance may lead to limited physical dependence or psychological
696 dependence relative to the substances in Schedule III.
697 8. The controlled substances listed in this subsection are included in Schedule IV:
698 (1) Any material, compound, mixture, or preparation containing any of the following
699 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited
700 quantities as set forth below:
701 (a) Not more than one milligram of difenoxin and not less than twenty-five
702 micrograms of atropine sulfate per dosage unit;
703 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
704 propionoxybutane);
705 (c) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical
706 and geometric isomers, and salts of these isomers (including tramadol);
707 (d) Anyofthefollowinglimitedquantitiesofnarcoticdrugsortheirsalts,whichshall
708 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to
709 confer upon the compound, mixture or preparation valuable medicinal qualities other than
710 those possessed by the narcotic drug alone:
HB 2213 21
711 a. Not more than two hundred milligrams of codeine per one hundred milliliters or
712 per one hundred grams;
713 b. Not more than one hundred milligrams of dihydrocodeine per one hundred
714 milliliters or per one hundred grams;
715 c. Not more than one hundred milligrams of ethylmorphine per one hundred
716 milliliters or per one hundred grams;
717 (2) Any material, compound, mixture or preparation containing any quantity of the
718 following substances, including their salts, isomers, and salts of isomers whenever the
719 existence of those salts, isomers, and salts of isomers is possible within the specific chemical
720 designation:
721 (a) Alfaxalone;
722 (b) Alprazolam;
723 (c) Barbital;
724 (d) Bromazepam;
725 (e) Camazepam;
726 (f) Carisoprodol;
727 (g) Chloral betaine;
728 (h) Chloral hydrate;
729 (i) Chlordiazepoxide;
730 (j) Clobazam;
731 (k) Clonazepam;
732 (l) Clorazepate;
733 (m) Clotiazepam;
734 (n) Cloxazolam;
735 (o) Delorazepam;
736 (p) Diazepam;
737 (q) Dichloralphenazone;
738 (r) Estazolam;
739 (s) Ethchlorvynol;
740 (t) Ethinamate;
741 (u) Ethyl loflazepate;
742 (v) Fludiazepam;
743 (w) Flunitrazepam;
744 (x) Flurazepam;
745 (y) Fospropofol;
746 (z) Halazepam;
747 (aa) Haloxazolam;
HB 2213 22
748 (bb) Ketazolam;
749 (cc) Loprazolam;
750 (dd) Lorazepam;
751 (ee) Lormetazepam;
752 (ff) Mebutamate;
753 (gg) Medazepam;
754 (hh) Meprobamate;
755 (ii) Methohexital;
756 (jj) Methylphenobarbital (mephobarbital);
757 (kk) Midazolam;
758 (ll) Nimetazepam;
759 (mm) Nitrazepam;
760 (nn) Nordiazepam;
761 (oo) Oxazepam;
762 (pp) Oxazolam;
763 (qq) Paraldehyde;
764 (rr) Petrichloral;
765 (ss) Phenobarbital;
766 (tt) Pinazepam;
767 (uu) Prazepam;
768 (vv) Quazepam;
769 (ww) Suvorexant;
770 (xx) Temazepam;
771 (yy) Tetrazepam;
772 (zz) Triazolam;
773 (aaa) Zaleplon;
774 (bbb) Zolpidem;
775 (ccc) Zopiclone;
776 (3) Any material, compound, mixture, or preparation which contains any quantity of
777 the following substance including its salts, isomers and salts of isomers whenever the
778 existence of such salts, isomers and salts of isomers is possible: fenfluramine;
779 (4) Any material, compound, mixture, or preparation which contains any quantity of
780 the following substances, including its salts, isomers, and salts of isomers, whenever the
781 existence of such salts, isomers, and salts of isomers is possible: Lorcaserin;
782 (5) Any material, compound, mixture or preparation containing any quantity of the
783 following substances having a stimulant effect on the central nervous system, including their
784 salts, isomers and salts of isomers:
HB 2213 23
785 (a) Cathine ((+)-norpseudoephedrine);
786 (b) Diethylpropion;
787 (c) Fencamfamin;
788 (d) Fenproporex;
789 (e) Mazindol;
790 (f) Mefenorex;
791 (g) Modafinil;
792 (h) Pemoline, including organometallic complexes and chelates thereof;
793 (i) Phentermine;
794 (j) Pipradrol;
795 (k) Sibutramine;
796 (l) SPA ((-)-1-dimethyamino-1,2-diphenylethane);
797 (6) Any material, compound, mixture or preparation containing any quantity of the
798 following substance, including its salts:
799 (a) Butorphanol (including its optical isomers);
800 (b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-
801 oxopropyl][(1S)-1-(4-phenyl-1 H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
802 acid) (including its optical isomers) and its salts, isomers, and salts of isomers;
803 (c) Pentazocine;
804 (7) Ephedrine, its salts, optical isomers and salts of optical isomers, when the
805 substance is the only active medicinal ingredient;
806 (8) The department of health and senior services may except by rule any compound,
807 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
808 subsection from the application of all or any part of sections 195.010 to 195.320 and sections
809 579.015 to 579.086 if the compound, mixture, or preparation contains one or more active
810 medicinal ingredients not having a depressant effect on the central nervous system, and if the
811 admixtures are included therein in combinations, quantity, proportion, or concentration that
812 vitiate the potential for abuse of the substances which have a depressant effect on the central
813 nervous system.
814 9. The department of health and senior services shall place a substance in Schedule V
815 if it finds that:
816 (1) The substance has low potential for abuse relative to the controlled substances
817 listed in Schedule IV;
818 (2) The substance has currently accepted medical use in treatment in the United
819 States; and
820 (3) The substance has limited physical dependence or psychological dependence
821 liability relative to the controlled substances listed in Schedule IV.
HB 2213 24
822 10. The controlled substances listed in this subsection are included in Schedule V:
823 (1) Any compound, mixture or preparation containing any of the following narcotic
824 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as
825 set forth below, which also contains one or more nonnarcotic active medicinal ingredients in
826 sufficientproportiontoconferuponthecompound,mixtureorpreparationvaluablemedicinal
827 qualities other than those possessed by the narcotic drug alone:
828 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
829 twenty-five micrograms of atropine sulfate per dosage unit;
830 (b) Notmorethanonehundredmilligramsofopiumperonehundredmillilitersorper
831 one hundred grams;
832 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
833 micrograms of atropine sulfate per dosage unit;
834 (2) Any material, compound, mixture or preparation which contains any quantity of
835 the following substance having a stimulant effect on the central nervous system including its
836 salts, isomers and salts of isomers: pyrovalerone;
837 (3) Any compound, mixture, or preparation containing any detectable quantity of
838 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
839 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
840 isomers, or salts of optical isomers;
841 (4) Unlessspecificallyexemptedorexcludedorunlesslistedinanotherschedule,any
842 material, compound, mixture, or preparation which contains any quantity of the following
843 substances having a depressant effect on the central nervous system, including its salts:
844 (a) Brivaracetam ((25)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also
845 referred to as BRV; UCB-34714; Briviact);
846 (b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl
847 ester];
848 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
849 (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid];
850 (5) Any drug product in finished dosage formulation that has been approved by the
851 U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-
852 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no
853 more than 0.1 percent (w/w) residual tetrahydro cannabinols.
854 11. If any compound, mixture, or preparation as specified in subdivision (3) of
855 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
856 prescription:
857 (1) All packages of any compound, mixture, or preparation containing any detectable
858 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or
HB 2213 25
859 ephedrine,itssaltsoropticalisomers,orsaltsofopticalisomers,shallbeofferedforsaleonly
860 from behind a pharmacy counter where the public is not permitted, and only by a registered
861 pharmacist or registered pharmacy technician; and
862 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
863 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical
864 isomers,or salts ofoptical isomers orephedrine, its salts or opticalisomers, or saltsof optical
865 isomers shall be at least eighteen years of age; and
866 (3) Thepharmacist,internpharmacist,orregisteredpharmacytechnicianshallrequire
867 any person, prior to such person's purchasing, receiving or otherwise acquiring such
868 compound, mixture, or preparation to furnish suitable photo identification that is issued by a
869 state or the federal government or a document that, with respect to identification, is
870 considered acceptable and showing the date of birth of the person;
871 (4) The seller shall deliver the product directly into the custody of the purchaser.
872 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
873 implement and maintain an electronic log of each transaction. Such log shall include the
874 following information:
875 (1) The name, address, and signature of the purchaser;
876 (2) The amount of the compound, mixture, or preparation purchased;
877 (3) The date and time of each purchase; and
878 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
879 technician who dispensed the compound, mixture, or preparation to the purchaser.
880 13. Each pharmacy shall submit information regarding sales of any compound,
881 mixture, or preparation as specified in subdivision (3) of subsection 10 of this section in
882 accordance with transmission methods and frequency established by the department by
883 regulation;
884 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
885 greater than those specified in this chapter.
886 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine
887 productsinapharmacyshallensurethatallsuchproductsarelocatedonlybehindapharmacy
888 counter where the public is not permitted.
889 16. The penalties for a knowing or reckless violation of the provisions of subsections
890 11 to 15 of this section are found in section 579.060.
891 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
892 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
893 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any
894 compound, mixture, or preparation specified in subdivision (3) of subsection 10 of this
HB 2213 26
895 section which must be dispensed, sold, or distributed in a pharmacy pursuant to a
896 prescription.
897 18. The manufacturer of a drug product or another interested party may apply with
898 the department of health and senior services for an exemption from this section. The
899 department of health and senior services may grant an exemption by rule from this section if
900 the department finds the drug product is not used in the illegal manufacture of
901 methamphetamine or other controlled or dangerous substances. The department of health
902 and senior services shall rely on reports from law enforcement and law enforcement
903 evidentiary laboratories in determining if the proposed product can be used to manufacture
904 illicit controlled substances.
905 19. The department of health and senior services shall revise and republish the
906 schedules annually.
907 20. Thedepartmentofhealthandseniorservicesshallpromulgaterulesunderchapter
908 536 regarding the security and storage of Schedule V controlled substances, as described in
909 subdivision (3) of subsection 10 of this section, for distributors as registered by the
910 department of health and senior services.
911 21. Logs of transactions required to be kept and maintained by this section and
912 section 195.417 shall create a rebuttable presumption that the person whose name appears in
913 the logs is the person whose transactions are recorded in the logs.
✔